Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-11-04
2009-11-24
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07622251
ABSTRACT:
The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.
REFERENCES:
patent: 4699877 (1987-10-01), Cline et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5015568 (1991-05-01), Tsujimoto et al.
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5459251 (1995-10-01), Tsujimoto et al.
patent: RE35491 (1997-04-01), Cline et al.
patent: 5670325 (1997-09-01), Lapidus et al.
patent: 5741650 (1998-04-01), Lapidus et al.
patent: 5830665 (1998-11-01), Shuber et al.
patent: 5830753 (1998-11-01), Coulie et al.
patent: 5858678 (1999-01-01), Chinnadurai
patent: 5861278 (1999-01-01), Wong et al.
patent: 5928870 (1999-07-01), Lapidus et al.
patent: 5952178 (1999-09-01), Lapidus et al.
patent: 5952179 (1999-09-01), Chinnadurai
patent: 5962312 (1999-10-01), Plowman et al.
patent: 5985553 (1999-11-01), King et al.
patent: 6020137 (2000-02-01), Lapidus et al.
patent: 6100029 (2000-08-01), Lapidus et al.
patent: 6143529 (2000-11-01), Lapidus et al.
patent: 6146828 (2000-11-01), Lapidus et al.
patent: 6171798 (2001-01-01), Levine et al.
patent: 6203993 (2001-03-01), Shuber et al.
patent: 6207401 (2001-03-01), Plowman et al.
patent: 6207452 (2001-03-01), Govindaswamy
patent: 6214558 (2001-04-01), Shuber et al.
patent: 6245523 (2001-06-01), Altieri
patent: 6248535 (2001-06-01), Danenberg et al.
patent: 6271002 (2001-08-01), Linsley et al.
patent: 6322986 (2001-11-01), Ross
patent: 6414134 (2002-07-01), Reed
patent: 6582919 (2003-06-01), Danenberg
patent: 6602670 (2003-08-01), Danenberg
patent: 6618679 (2003-09-01), Loehrlein et al.
patent: 6620606 (2003-09-01), Bandman et al.
patent: 6696558 (2004-02-01), Reed et al.
patent: 6716575 (2004-04-01), Plowman et al.
patent: 6750013 (2004-06-01), Gish et al.
patent: 6800737 (2004-10-01), Altieri
patent: 6943150 (2005-09-01), Altieri
patent: 2002/0004491 (2002-01-01), Xu et al.
patent: 2002/0009736 (2002-01-01), Wang
patent: 2002/0039764 (2002-04-01), Rosen
patent: 2002/0160395 (2002-10-01), Altieri et al.
patent: 2003/0073112 (2003-04-01), Zhang et al.
patent: 2003/0104499 (2003-06-01), Pressman et al.
patent: 2003/0165952 (2003-09-01), Linnarsson et al.
patent: 2003/0180791 (2003-09-01), Chinnadurai
patent: 2003/0198970 (2003-10-01), Roberts
patent: 2003/0198972 (2003-10-01), Erlander et al.
patent: 2003/0219771 (2003-11-01), Bevilacqua et al.
patent: 2003/0229455 (2003-12-01), Bevilacqua et al.
patent: 2004/0009489 (2004-01-01), Golub et al.
patent: 2004/0126775 (2004-07-01), Altieri et al.
patent: 2004/0133352 (2004-07-01), Bevilacqua et al.
patent: 2005/0048542 (2005-03-01), Baker et al.
patent: 0 108 564 (1988-05-01), None
patent: 1 365 034 (2003-11-01), None
patent: WO 99/02714 (1999-01-01), None
patent: WO 00/50595 (2000-08-01), None
patent: WO 00/55173 (2000-09-01), None
patent: WO 01/25250 (2001-04-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 01/55320 (2001-08-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO 02/00677 (2002-01-01), None
patent: WO 02/06526 (2002-01-01), None
patent: WO 02/08260 (2002-01-01), None
patent: WO 02/08261 (2002-01-01), None
patent: WO 02/08282 (2002-01-01), None
patent: WO 02/08765 (2002-01-01), None
patent: WO 02/46467 (2002-06-01), None
patent: WO 02/017852 (2002-07-01), None
patent: WO 02/055988 (2002-07-01), None
patent: WO 02/059377 (2002-08-01), None
patent: WO 02/068579 (2002-09-01), None
patent: WO 02/103320 (2002-12-01), None
patent: WO 03/011897 (2003-02-01), None
patent: WO 03/078662 (2003-09-01), None
patent: WO 03/083096 (2003-10-01), None
patent: WO 2004/065583 (2004-08-01), None
Kuukasjarvi et al (Journal of Clinical Oncology, “Loss of Estrogen Receptor in Recurrent Breast Cancer Is Associated With Poor Response to Endocrine Therapy”, Sep. 1996, 14(9):2584-2589).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Gasparini et al (Clinical Cancer Research, Feb. 1995, 1: 189-198).
Zhang et al (Clinical Cancer Research, Oct. 1999, 5: 2971-2977).
Barrett-Lee et al (Cancer Research, Dec. 1987, 47:6653-6659).
Vollenweider-Zerargui et al (Cancer, 1986, 57:1171-1180).
Carmeci et al (Am J Pathol, May 1997, 150(5): 1563-70).
Brabender, Jan, et al.;Epidermal Growth Factor Receptor and HER2-neu mRNA Expression in Non-Small Cell Lung Cancer Is Correlated with Survival, Clinical Cancer Research; vol. 7, Jul. 2001; pp. 1850-1855.
Ding, Chunming, et al.;A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS, PNAS, vol. 100:6; Mar. 18, 2003; pp. 3059-3064.
Cambridge Healthtech Institute Conference Agenda; “Enabling Molecular Profiling With Cellular Resolution: Microgenomics Using Homogeneous Cell Samples”; Dec. 2002; 5 pgs.
Yang, Li, et al.;BADGE,BeadsArray for theDetection ofGeneExpression, a High-Throughput Diagnostic Bioassay; Genome Research; vol. 11; 2001; pp. 1888-1898.
Ayers, M. et al., “Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer,”Journal of Clinical Oncology, 22:(12), 2004, pp. 2284-2293.
Garber, K. et al., “Gene Expression Tests Foretell Breast Cancer's Future,”Science, 303:(5665), 2004, pp. 1754-1755.
Jansen, M. et al., Molecular Classification of Tamoxifen-Responsive and -Resistant Breast Carcinomas by Gene Expression Profiling,Breast Cancer Research and Treatment, 82:(Supplement 1.), 2003, p. S14.
Los, G. et al., “Using mRNA Expression Profiling to Determine Anticancer Drug Efficacy,”Cytometry, 47:(1), 2002, pp. 66-71.
Paik, S. et al., “A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer,”The New England Journal of Medicine, 351:(27), 2004, pp. 2817-2826.
Palk, S. et al., “Multi-Gene RT-PCR Assay for Predicting Recurrence in Node Negative Breast Cancer Patients-NSABP Studies B-20 and B-14,”Breast Cancer Research and Treatment, 82:(Supplement 1.), 2003, pp. S10-S11.
Ravdin, P.M. et al., “Computer Program to Assist in Making Decisions about Adjuvant Therapy for Women with Early Breast Cancer,”Journal of Clinical Oncology, 19:(4), 2001, pp. 980-991.
Fisher, B., et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from national surgical adjuvant breast and bowel project protocol B-06. Journal of Clinical Oncology. 1988, vol. 6, No. 7, pp. 1076-1087.
Kononen, J., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine. 1998, vol. 4, No. 7, pp. 844-847.
Lah, T., et al. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: Comparison with cathepsin D, cathepsin L, and other clinical indicators. Clinical Cancer Research. 2000, vol. 6, pp. 578-584.
Miyoshi, Y., et al. Association of centrosomal kinase STK15/BTAK MRNA expression with chromosomal instability in human breast cancers. 2001, vol. 92, pp. 370-373.
Modlich, O., et al. Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. Journal of Translational Medicine. 2005, vol. 3 pp. 32.
Nakopoulou, L., e
Baker Joffre B.
Bryant John L.
Paik Soonmyung
Shak Steven
Aeder Sean E
Bozicevic Field & Francis LLP
Francis Carol L.
Genomic Health, Inc.
Keddie James S.
LandOfFree
Molecular indicators of breast cancer prognosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular indicators of breast cancer prognosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular indicators of breast cancer prognosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4126093